ATE395056T1 - Verwendung von r-(+)-2-(3-diisopropylamino-1- phenylpropyl)-4-hydroxy-methyl- phenylisobuttersäureester hydrogenfumarat zur behandlung von harndrang-inkontinenz und anderen spasmogenen leiden - Google Patents
Verwendung von r-(+)-2-(3-diisopropylamino-1- phenylpropyl)-4-hydroxy-methyl- phenylisobuttersäureester hydrogenfumarat zur behandlung von harndrang-inkontinenz und anderen spasmogenen leidenInfo
- Publication number
- ATE395056T1 ATE395056T1 AT06011207T AT06011207T ATE395056T1 AT E395056 T1 ATE395056 T1 AT E395056T1 AT 06011207 T AT06011207 T AT 06011207T AT 06011207 T AT06011207 T AT 06011207T AT E395056 T1 ATE395056 T1 AT E395056T1
- Authority
- AT
- Austria
- Prior art keywords
- diisopropylamino
- phenylpropyl
- hydroxy
- methyl
- treatment
- Prior art date
Links
- AGPKNHUKPQYLCB-IREOKEETSA-N (2R)-5-[di(propan-2-yl)amino]-2-[1-(4-hydroxyphenyl)ethyl]-2-methyl-3-phenylpentanoic acid Chemical compound C(C)(C)N(CCC(C1=CC=CC=C1)[C@](C(=O)O)(C(C1=CC=C(C=C1)O)C)C)C(C)C AGPKNHUKPQYLCB-IREOKEETSA-N 0.000 title 1
- 206010046543 Urinary incontinence Diseases 0.000 title 1
- 150000002148 esters Chemical class 0.000 title 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 title 1
- 230000003033 spasmogenic effect Effects 0.000 title 1
- KISZTEOELCMZPY-UHFFFAOYSA-N 3,3-diphenylpropylamine Chemical class C=1C=CC=CC=1C(CCN)C1=CC=CC=C1 KISZTEOELCMZPY-UHFFFAOYSA-N 0.000 abstract 1
- -1 Diphenylpropylamine derivative salts Chemical class 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 239000000812 cholinergic antagonist Substances 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229940051806 diphenylpropylamine derivative analgesics Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002048 spasmolytic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
- Luminescent Compositions (AREA)
- Detergent Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19955190A DE19955190A1 (de) | 1999-11-16 | 1999-11-16 | Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE395056T1 true ATE395056T1 (de) | 2008-05-15 |
Family
ID=7929277
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06011207T ATE395056T1 (de) | 1999-11-16 | 2000-11-15 | Verwendung von r-(+)-2-(3-diisopropylamino-1- phenylpropyl)-4-hydroxy-methyl- phenylisobuttersäureester hydrogenfumarat zur behandlung von harndrang-inkontinenz und anderen spasmogenen leiden |
| AT00989857T ATE286872T1 (de) | 1999-11-16 | 2000-11-15 | Stabile salze neuartiger derivate von 3,3- diphenylpropylaminen |
| AT04018487T ATE337293T1 (de) | 1999-11-16 | 2000-11-15 | Stabile salze neuartiger derivative von 3,3- diphenylpropylaminen |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00989857T ATE286872T1 (de) | 1999-11-16 | 2000-11-15 | Stabile salze neuartiger derivate von 3,3- diphenylpropylaminen |
| AT04018487T ATE337293T1 (de) | 1999-11-16 | 2000-11-15 | Stabile salze neuartiger derivative von 3,3- diphenylpropylaminen |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6858650B1 (enExample) |
| EP (3) | EP1481964B1 (enExample) |
| JP (6) | JP4083431B2 (enExample) |
| KR (2) | KR100536095B1 (enExample) |
| CN (1) | CN1215045C (enExample) |
| AT (3) | ATE395056T1 (enExample) |
| AU (1) | AU778132B2 (enExample) |
| BR (1) | BRPI0015610C1 (enExample) |
| CA (1) | CA2389749C (enExample) |
| CY (2) | CY1106204T1 (enExample) |
| CZ (2) | CZ302497B6 (enExample) |
| DE (5) | DE29923134U1 (enExample) |
| DK (3) | DK1690536T3 (enExample) |
| EA (1) | EA005588B1 (enExample) |
| ES (3) | ES2236032T7 (enExample) |
| GE (1) | GEP20084430B (enExample) |
| HK (1) | HK1045148B (enExample) |
| HU (2) | HU227608B1 (enExample) |
| IL (2) | IL149567A0 (enExample) |
| IS (2) | IS2124B (enExample) |
| MX (1) | MXPA02004603A (enExample) |
| NO (2) | NO323920B1 (enExample) |
| NZ (1) | NZ519230A (enExample) |
| PL (1) | PL201422B1 (enExample) |
| PT (3) | PT1690536E (enExample) |
| SI (3) | SI1230209T1 (enExample) |
| SK (3) | SK287430B6 (enExample) |
| UA (2) | UA73324C2 (enExample) |
| WO (1) | WO2001035957A1 (enExample) |
| ZA (1) | ZA200203315B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| DE29923134U1 (de) * | 1999-11-16 | 2000-06-29 | Schwarz Pharma Ag, 40789 Monheim | Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen |
| DE10028443C1 (de) * | 2000-06-14 | 2002-05-29 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen |
| DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
| DE10315878B4 (de) * | 2003-04-08 | 2009-06-04 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung |
| WO2005012227A2 (en) * | 2003-08-05 | 2005-02-10 | Ranbaxy Laboratories Limited | Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine |
| ES2235648B1 (es) * | 2003-12-22 | 2006-11-01 | Ragactives, S.L. | Procedimiento para la obtencion de tolterodina. |
| US8034823B2 (en) | 2005-02-22 | 2011-10-11 | Savvipharm Inc | Method of increasing drug oral bioavailability and compositions of less toxic orotate salts |
| KR100647068B1 (ko) | 2005-09-15 | 2006-11-23 | 하나제약 주식회사 | 라세믹ｎ,ｎ-디이소프로필-3-(2-히드록시-5-메틸페닐)-3-페닐프로판아민의 제조방법 |
| US8067594B2 (en) * | 2006-05-24 | 2011-11-29 | Pfizer Inc. | Process for the production of benzopyran-2-ol derivatives |
| EP1862449A1 (en) * | 2006-05-31 | 2007-12-05 | Schwarz Pharma Ltd. | A shortened synthesis of substituted hydroxymethyl phenols |
| EP1940774B1 (en) * | 2006-05-31 | 2014-03-05 | Schwarz Pharma Ltd. | New synthesis of substituted hydroxymethyl phenols |
| IES20060424A2 (en) * | 2006-06-08 | 2007-10-31 | Schwarz Pharma Ltd | Accelerated synthesis of (3-Diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol and its phenolic monoesters |
| US7807715B2 (en) | 2006-06-09 | 2010-10-05 | Ucb Pharma Gmbh | Pharmaceutical compositions comprising fesoterodine |
| PE20080331A1 (es) * | 2006-06-09 | 2008-06-19 | Sanol Arznei Schwarz Gmbh | Composiciones farmaceuticas estabilizadas que comprenden fesoterodina |
| ATE477234T1 (de) | 2006-06-09 | 2010-08-15 | Schwarz Pharma Ltd | Synthese von phenolischen estern von hydroxymethylphenolen |
| BRPI0712842A2 (pt) * | 2006-06-12 | 2012-07-24 | Sanol Arznei Schwarz Gmbh | internediÁrio quiral, processo para produÇço do mesmo e seu emprego na fabricaÇço da tolterodina, fesoterodina ou o metabàlito ativo das mesmas. |
| IES20060435A2 (en) | 2006-06-12 | 2007-12-12 | Schwarz Pharma Ltd | Shortened synthesis using paraformaldehyde or trioxane |
| WO2009037569A2 (en) * | 2007-09-21 | 2009-03-26 | Actavis Group Ptc Ehf | An improved process for the preparation of fesoterodine |
| US20100297241A1 (en) * | 2007-10-01 | 2010-11-25 | Actavis Group Ptc Ehf | Amorphous Fesoterodine Fumarate |
| EP2294047A2 (en) * | 2008-04-04 | 2011-03-16 | Actavis Group PTC EHF | Novel mandelate salt of fesoterodine |
| EP2323967A2 (en) * | 2008-07-21 | 2011-05-25 | Actavis Group PTC EHF | Fesoterodine comprising a reduced amount of dehydroxyfesoterodine |
| IT1392082B1 (it) * | 2008-12-10 | 2012-02-09 | Chemi Spa | Nuove forme solide della fesoterodina fumarato |
| MX2011011937A (es) | 2009-05-11 | 2012-01-27 | Ratiopharm Gmbh | Desfesoterodina en la forma de una sal del acido tartarico. |
| IT1394219B1 (it) * | 2009-05-15 | 2012-06-01 | Chemi Spa | Metodo di preparazione di fesoterodina fumarato di elevata purezza. |
| IT1394217B1 (it) * | 2009-05-15 | 2012-06-01 | Chemi Spa | Metodo di preparazione di fesoterodina e/o fesoterodina fumarato. |
| US20120220655A1 (en) | 2009-09-03 | 2012-08-30 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Crystalline forms of fesoterodine fumarate and fesoterodine base |
| IT1396373B1 (it) * | 2009-10-29 | 2012-11-19 | Dipharma Francis Srl | Procedimento per la preparazione di fesoterodina. |
| EP2316432A1 (de) | 2009-10-30 | 2011-05-04 | ratiopharm GmbH | Zusammensetzung enthaltend Fesoterodin und Ballaststoffe |
| US20110124903A1 (en) * | 2009-11-20 | 2011-05-26 | Actavis Group Ptc Ehf | Solid state forms of fesoterodine intermediates |
| IT1397521B1 (it) * | 2009-12-21 | 2013-01-16 | Dipharma Francis Srl | Procedimento per la preparazione di fesoterodina con un basso contenuto di impurezze. |
| IT1397920B1 (it) * | 2010-02-08 | 2013-02-04 | Dipharma Francis Srl | Forma cristallina di fesoterodina fumarato e procedimento per la sua preparazione |
| EP2549985A1 (en) | 2010-03-22 | 2013-01-30 | Cadila Healthcare Limited | Stable pharmaceutical compositions comprising fesoterodine |
| US8748433B2 (en) | 2010-04-30 | 2014-06-10 | Merck Sharp & Dohme Corp. | β3 adrenergic receptor agonists |
| WO2011141932A2 (en) | 2010-05-11 | 2011-11-17 | Intas Pharmaceuticals Limited | Process for preparation of phenolic monoesters of hydroxymethyl phenols |
| WO2011145019A1 (en) * | 2010-05-17 | 2011-11-24 | Orchid Chemicals And Pharmaceuticals Limited | Improved process for diphenylpropylamine derivatives |
| IT1401451B1 (it) | 2010-06-10 | 2013-07-26 | Chemi Spa | Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo. |
| WO2011158257A1 (en) | 2010-06-18 | 2011-12-22 | Panacea Biotec Ltd | Preparation process of fesoterodine and intermediates |
| WO2012025941A2 (en) | 2010-08-25 | 2012-03-01 | Cadila Healthcare Limited | Processes for the preparation of fesoterodine |
| IT1403094B1 (it) * | 2010-12-09 | 2013-10-04 | Dipharma Francis Srl | Procedimento per la preparazione di fesoterodina o un suo sale |
| WO2012098560A2 (en) * | 2011-01-17 | 2012-07-26 | Msn Laboratories Limited | Process for the preparation of muscarinic receptor antagonist |
| TWI520732B (zh) | 2011-01-18 | 2016-02-11 | 輝瑞有限公司 | 固體分子分散液 |
| EP2508173A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Stabilized pharmaceutical composition comprising fesoterodine |
| EP2508175A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof |
| US9422228B2 (en) | 2012-05-04 | 2016-08-23 | Crystal Pharma, S.A.U. | Process for the preparation of optically pure fesoterodine derivatives |
| ITMI20121232A1 (it) | 2012-07-16 | 2014-01-17 | Cambrex Profarmaco Milano Srl | Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati |
| TR201721437A2 (tr) | 2017-12-25 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari |
| CN116472262A (zh) * | 2020-10-27 | 2023-07-21 | 威娜德国有限责任公司 | 化妆品级品质的2-甲氧基甲基-对苯二胺 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ198953A (en) * | 1980-11-14 | 1984-10-19 | Lilly Co Eli | (-)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamine,its salts and pharmaceutical formulations |
| IL66831A0 (en) * | 1981-10-05 | 1982-12-31 | Kefalas As | Indane derivatives |
| SE8800207D0 (sv) * | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | Nya aminer, deras anvendning och framstellning |
| EP0445749B1 (en) * | 1990-03-08 | 1996-07-10 | Fujisawa Pharmaceutical Co., Ltd. | N-Monosubstituted cyclopentenylamines, a process for their preparation and their use as medicaments |
| JPH0483431A (ja) * | 1990-07-26 | 1992-03-17 | Seiko Epson Corp | 選択呼出受信機 |
| SE9203318D0 (sv) | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
| SE9701144D0 (sv) * | 1997-03-27 | 1997-03-27 | Pharmacia & Upjohn Ab | Novel compounds, their use and preparation |
| EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| DE29923134U1 (de) * | 1999-11-16 | 2000-06-29 | Schwarz Pharma Ag, 40789 Monheim | Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen |
-
1999
- 1999-11-16 DE DE29923134U patent/DE29923134U1/de not_active Expired - Lifetime
- 1999-11-16 DE DE19955190A patent/DE19955190A1/de not_active Ceased
-
2000
- 2000-11-15 US US10/130,214 patent/US6858650B1/en not_active Expired - Lifetime
- 2000-11-15 NZ NZ519230A patent/NZ519230A/en not_active IP Right Cessation
- 2000-11-15 CZ CZ20060247A patent/CZ302497B6/cs not_active IP Right Cessation
- 2000-11-15 BR BRPI0015610A patent/BRPI0015610C1/pt not_active IP Right Cessation
- 2000-11-15 EP EP04018487A patent/EP1481964B1/de not_active Expired - Lifetime
- 2000-11-15 CN CNB008157057A patent/CN1215045C/zh not_active Expired - Lifetime
- 2000-11-15 JP JP2001537950A patent/JP4083431B2/ja not_active Expired - Lifetime
- 2000-11-15 PL PL356766A patent/PL201422B1/pl unknown
- 2000-11-15 UA UA2002043609A patent/UA73324C2/uk unknown
- 2000-11-15 EP EP00989857A patent/EP1230209B3/de not_active Expired - Lifetime
- 2000-11-15 DK DK06011207T patent/DK1690536T3/da active
- 2000-11-15 HK HK02106545.5A patent/HK1045148B/zh not_active IP Right Cessation
- 2000-11-15 PT PT06011207T patent/PT1690536E/pt unknown
- 2000-11-15 SK SK657-2002A patent/SK287430B6/sk not_active IP Right Cessation
- 2000-11-15 SK SK5024-2013A patent/SK288384B6/sk not_active IP Right Cessation
- 2000-11-15 DE DE50015163T patent/DE50015163D1/de not_active Expired - Lifetime
- 2000-11-15 SI SI200030617T patent/SI1230209T1/xx unknown
- 2000-11-15 KR KR10-2002-7006306A patent/KR100536095B1/ko not_active Expired - Fee Related
- 2000-11-15 AT AT06011207T patent/ATE395056T1/de active
- 2000-11-15 IL IL14956700A patent/IL149567A0/xx unknown
- 2000-11-15 PT PT04018487T patent/PT1481964E/pt unknown
- 2000-11-15 PT PT00989857T patent/PT1230209E/pt unknown
- 2000-11-15 DK DK04018487T patent/DK1481964T3/da active
- 2000-11-15 SI SI200030998T patent/SI1690536T1/sl unknown
- 2000-11-15 CA CA002389749A patent/CA2389749C/en not_active Expired - Lifetime
- 2000-11-15 SI SI200030890T patent/SI1481964T1/sl unknown
- 2000-11-15 HU HU0900587A patent/HU227608B1/hu unknown
- 2000-11-15 AT AT00989857T patent/ATE286872T1/de active
- 2000-11-15 AT AT04018487T patent/ATE337293T1/de active
- 2000-11-15 DE DE50013365T patent/DE50013365D1/de not_active Expired - Lifetime
- 2000-11-15 MX MXPA02004603A patent/MXPA02004603A/es active IP Right Grant
- 2000-11-15 ES ES00989857T patent/ES2236032T7/es active Active
- 2000-11-15 DE DE50009239T patent/DE50009239D1/de not_active Expired - Lifetime
- 2000-11-15 CZ CZ20021343A patent/CZ302967B6/cs not_active IP Right Cessation
- 2000-11-15 ES ES06011207T patent/ES2303708T3/es not_active Expired - Lifetime
- 2000-11-15 DK DK00989857T patent/DK1230209T3/da active
- 2000-11-15 ES ES04018487T patent/ES2270240T3/es not_active Expired - Lifetime
- 2000-11-15 SK SK5027-2010A patent/SK288185B6/sk not_active IP Right Cessation
- 2000-11-15 WO PCT/EP2000/011309 patent/WO2001035957A1/de not_active Ceased
- 2000-11-15 EP EP06011207A patent/EP1690536B1/de not_active Expired - Lifetime
- 2000-11-15 AU AU26667/01A patent/AU778132B2/en not_active Expired
- 2000-11-15 EA EA200200511A patent/EA005588B1/ru not_active IP Right Cessation
- 2000-11-15 KR KR1020057018318A patent/KR100563149B1/ko not_active Expired - Lifetime
- 2000-11-15 HU HU0204034A patent/HU228197B1/hu unknown
-
2002
- 2002-04-19 IS IS6351A patent/IS2124B/xx unknown
- 2002-04-25 ZA ZA200203315A patent/ZA200203315B/xx unknown
- 2002-05-09 IL IL149567A patent/IL149567A/en active IP Right Grant
- 2002-05-15 NO NO20022314A patent/NO323920B1/no not_active IP Right Cessation
-
2005
- 2005-01-17 UA UAA200500434A patent/UA77322C2/uk unknown
-
2006
- 2006-03-29 IS IS8382A patent/IS2673B/is unknown
- 2006-10-18 CY CY20061101493T patent/CY1106204T1/el unknown
- 2006-11-22 NO NO20065380A patent/NO332637B1/no not_active IP Right Cessation
-
2007
- 2007-02-22 JP JP2007042774A patent/JP2007137895A/ja active Pending
- 2007-11-07 GE GEAP200710360A patent/GEP20084430B/en unknown
-
2008
- 2008-07-08 CY CY20081100712T patent/CY1110389T1/el unknown
-
2010
- 2010-04-22 JP JP2010098844A patent/JP5650924B2/ja not_active Expired - Lifetime
- 2010-04-22 JP JP2010098845A patent/JP5503393B2/ja not_active Expired - Lifetime
-
2011
- 2011-04-25 JP JP2011096911A patent/JP5290351B2/ja not_active Expired - Lifetime
-
2013
- 2013-11-05 JP JP2013229622A patent/JP5717824B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE395056T1 (de) | Verwendung von r-(+)-2-(3-diisopropylamino-1- phenylpropyl)-4-hydroxy-methyl- phenylisobuttersäureester hydrogenfumarat zur behandlung von harndrang-inkontinenz und anderen spasmogenen leiden | |
| PT1780197E (pt) | 5-substituinte-2-fenilamino benzamida como inibidor de mek | |
| SE9903760D0 (sv) | New compounds | |
| SE9904176D0 (sv) | New use | |
| DE60021873D1 (de) | Zubereitung zur prophylaxe oder behandlung der demenz-erkrankung enthaltend ein hydroxyzimtsäurederivat oder einen extrakt einer pflanze der gattung angelica, der diese säure enthält. | |
| ATE416161T1 (de) | Zur behandlung von entzündungen geeignete indole | |
| BR0311425A (pt) | Composto, pró-droga, método para preparar o composto, álcool oticamente ativo, e amina oticamemte ativa, e para prevenir e/ou tratar anormalidades ou doenças, medicamento, e, uso do composto ou de uma pró-droga deste | |
| ATE357918T1 (de) | Verwendung von 2-(4-ethoxy-phenyl)-3-(4- methanesulfonyl-phenyl)-pyrazolo(1,5-b)pyridazi e zur behandlung von nichtulzerativer dyspepsie | |
| DK1272481T3 (da) | 4-Flouralkyl-2H-benzopyraner med antiöstrogen virkning | |
| DE69707372D1 (de) | Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne | |
| ATE281831T1 (de) | Verwendung eines mittels zur zur vorbeugung oder behandlung von durch anomalitäten des knorpelgewebes verursachten erkrankungen | |
| DE60216239T8 (de) | Verwendung von Cyclohexenon-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Dysurie | |
| ATE444961T1 (de) | Verbindungen vom hydrazidtyp und deren verwendung in pharmazeutischen zusammensetzungen zur behandlung von herzkreislauferkrankungen | |
| SE0300705D0 (sv) | New compounds | |
| SE0104333D0 (sv) | Therapeutic agents | |
| ES2062111T3 (es) | Empleo de 2,2,6,6-tetrametil-4-aminopiperidinamidas como fungicidas. | |
| ATE430132T1 (de) | Zur behandlung von entzündungen geeignete indole | |
| ATE479695T1 (de) | Sulfopyranosylacylglycerol-derivate zur anwendung in kombination mit bestrahlung in einer tumor- radiotherapie | |
| DE60018647T8 (de) | Verwendung von 4,6-Dimethoxyindol-2-carbonsäure oder ihren Derivaten zur Behandlung von Seborrhoe | |
| UA4482U (uk) | Спосіб дезінфекції об'єктів, які використовуються в шовківництві | |
| RU2001119804A (ru) | Средство для подавления роста сульфатвосстанавливающих бактерий |